P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.

Bibliographic Details
Main Authors:	Daniele Sannipoli, Gariazzo Camilla, Francesca Farina, Elisa Diral, Alessandro Bruno, Daniela Clerici, Sarah Marktel, Luca Canziani, Gloria Catalano, Paolo Fiore, Chiara Oltolini, Patrizia Rovere Querini, Consuelo Corti, Fabio Ciceri, Giordano Vitali, Maria Teresa Lupo-Stanghellini
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973164.50042.3f

Similar Items

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
by: Francesca Farina, et al.
Published: (2023-08-01)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
by: Francesca Farina, et al.
Published: (2023-08-01)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
by: D. wang, et al.
Published: (2022-06-01)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
by: Xiangke Xin, et al.
Published: (2025-02-01)

RIC VS MAC IN ALLO-HSCT FOR CHILDHOOD MYELODYSPLASTIC SYNDROME
by: Elena Morozova, et al.
Published: (2023-12-01)

TBI/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL/ALL
by: Jinghua Mao, et al.
Published: (2024-09-01)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
by: Shengnan Zhou, et al.
Published: (2023-08-01)

Sorafenib maintenance in FLT3-ITD mutated AML after allogeneic HCT: a real-world, single-center experience
by: Elisa Diral, et al.
Published: (2024-06-01)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
by: Elisa Diral, et al.
Published: (2023-08-01)

Coadministration of isavuconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients
by: Francesca Farina, et al.
Published: (2024-09-01)

Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
by: Emma Das-Gupta, et al.
Published: (2019-12-01)

Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT
by: Meiai Liao, et al.
Published: (2024-07-01)

Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM
by: Krzysztof Kalwak, et al.
Published: (2025-02-01)

Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT
by: Aliénor Xhaard, et al.
Published: (2017-08-01)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
by: J. M. Cerezo-Martin, et al.
Published: (2022-06-01)

Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature
by: Can Chen, et al.
Published: (2024-01-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
by: Maria Teresa Lupo-Stanghellini, et al.
Published: (2021-11-01)

Severe late onset capillary leak syndrome post allo-HSCT successfully treated by bevacizumab: a case report
by: Song Xue, et al.
Published: (2025-01-01)

CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
by: M. I. Zaraiski
Published: (2014-07-01)

Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
by: Wen-Jing Yu, et al.
Published: (2024-12-01)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
by: Zhangjie Chen, et al.
Published: (2023-08-01)

Application of metagenomic next-generation sequencing in the clinical diagnosis of infectious diseases after allo-HSCT: a single-center analysis
by: Hailong Yuan, et al.
Published: (2024-03-01)

The question of paper in Os Lusíadas, 1572
by: B Penafiel, A
Published: (2020)

The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT
by: Luke Maggs, et al.
Published: (2017-08-01)

Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review
by: Xuan Liu, et al.
Published: (2024-10-01)

Monocytes in allo-HSCT with aged donors secrete IL-1/IL-6/TNF to increase the risk of GVHD and damage the aged HSCs
by: Xia Li, et al.
Published: (2024-03-01)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
by: Shiyu Deng, et al.
Published: (2023-08-01)

Minnesota acute graft-<i>versus</i>-host disease risk score predicts survival at onset of graft-<i>versus</i>-host disease after post-transplant cyclophosphamide prophylaxis
by: Federica Ardizzoia, et al.
Published: (2022-07-01)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
by: Ming Sun, et al.
Published: (2023-08-01)

Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT
by: Rongtao Xue, et al.
Published: (2025-02-01)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
by: M. chen, et al.
Published: (2022-06-01)

High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies
by: Giovanni Mori, et al.
Published: (2024-01-01)

The hospitals of London: administration, refoundation, and benefaction, c.1500-1572
by: Daly, CT
Published: (1993)

Tudor noble commemoration and identity: the Howard family in context, 1485-1572
by: Claiden-Yardley, K
Published: (2014)

Projects of the Franco-Swedish Alliance against the Russian State in 1572–1575
by: S. M. Ryabov
Published: (2024-12-01)

Adana'da 1572 Yılında Kullanılan Türk Erkek Şahıs Adları
by: Yılmaz Kurt
Published: (1993-04-01)

Transformation of (allo)securinine to (allo)norsecurinine via a molecular editing strategy
by: Seoyoung Kim, et al.
Published: (2024-01-01)

Marina Pak (c. 1572–1636): An Attempted Reconstruction of Her Years in the Philippines
by: Hayoung Wong
Published: (2022-07-01)

Spontaneous remission of choroidal involvement by chronic myelomonocytic leukemia: a case report
by: Elisa Diral, et al.
Published: (2024-05-01)